Current HRT Use Increases Ovarian Cancer Risk


Even brief use of hormone replacement therapy in menopause can increase risk of the 2 most common forms of ovarian cancer, a meta-analysis finds.

Using hormone replacement therapy (HRT) during menopause, even briefly, is associated with an increased risk of the 2 most common forms of ovarian cancer, a recent meta-analysis suggests.

The study, which involved reviewing 52 epidemiological studies of women with ovarian cancer, found there is about 1 extra case of ovarian cancer for every 1000 women who take hormones for 5 years starting around age 50. In terms of deaths, the data suggests that 1 additional woman will die from ovarian cancer for every 1700 women who take HRT.

Key Points:

- Use of HRT is associated with a significantly increased risk of the 2 most common types of ovarian cancer.

- This risk is greatest during use of HRT and diminishes after the treatment is discontinued.

- Researchers suggest this risk should be strongly considered when evaluating options for managing symptoms of menopause.

The increased risk, however, was only found when looking at serous and endometrioid ovarian cancers, and the correlation was not found when researchers looked at the data involving the 2 less common types of ovarian cancers, mucinous and clear cell.

The effect of using hormone therapy on the risk of developing ovarian cancer was the same for the two main types of therapy prescribed: estrogen only, or estrogen combined with a progestogen, the analysis revealed. In addition, the authors found that the proportional increase in risk was not materially affected by the age at which replacement therapy began, body size, past use of oral contraceptives, hysterectomy, alcohol use, tobacco use, or family history of breast or ovarian cancer.

The risk is greatest in women currently on hormone therapy, and the risk falls after the therapy ends, the authors report. The data strongly suggests there is a causal relationship between developing ovarian cancer and using hormone therapy, the authors concluded. They suggest the medical advice and guidelines on the practice of using hormone therapy should be influenced by their analysis.

Finally, the increased risk associated with taking hormone therapy was documented among women who used the therapy for less than 5 years.

This analysis has been published in The Lancet.

Related Videos
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit:
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit:
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit:
New data shows elinzanetant's efficacy in treating menopausal symptoms | Image Credit:
Navigating vasomotor symptoms in breast cancer patients | Image Credit:
Fertility counseling for oncology patients | Image Credit:
Revolutionizing menopause management: A deep dive into fezolinetant | Image Credit:
Hot flashes poorly impact sleep quality | Image Credit:
How to manage bone health in midlife women | Image Credit: -
Mary Jane Minkin, MD, discusses The Menopause Society 2023 Annual Meeting | Image Credit: Yale School of Medicine
Related Content
© 2024 MJH Life Sciences

All rights reserved.